Comparison Between Infant Flow SiPAP and Noninvasive NAVA in the Neonatal Intensive Care Unit
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
When babies are born premature, they often need help with their breathing. The equipment used to help them breathe is not very comfortable and they sometimes need to be put on a specialized breathing machine with a tube into their lungs. The breathing machine or ventilator can be damaging to the newborn's lungs and more damage can occur the longer the newborn stays on a ventilator leading to chronic lung disease later in their lives. A new device called neurally adjusted ventilatory assist or NAVA is available that the investigators believe may be more comfortable for the premature newborn and may help the baby come off breathing support sooner. When using this device, babies may not need to be put on a ventilator and can avoid the lung damage associated with the breathing tube and the ventilator. The objective of this pilot study is to compare this new breathing device called NAVA, to the equipment that is currently being used, called SiPAP, to support premature newborn's breathing after birth without a breathing tube. The investigators hope to show that with this new technology, premature newborns that are having a difficult time breathing, will come off breathing support sooner compared to the breathing machines that are currently being used. The hypothesis for this proposed study is that improved synchrony with noninvasive NAVA will decrease time spent on noninvasive ventilation and avoid intubation.
| Condition | Intervention |
|---|---|
|
Respiratory Distress Syndrome |
Device: Neurally Adjusted Ventilatory Assist (NAVA) Device: SiPAP - placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study Comparing Infant Flow SiPAP to Noninvasive NAVA |
- total duration of respiratory support which includes both days and hours on NAVA/SiPAP (DORS) [ Time Frame: one year ] [ Designated as safety issue: No ]
- Proportion of infants that required escalation to increased noninvasive respiratory support (BiPhasic or increasing NAVA levels) or intubation and mechanical ventilation [ Time Frame: one year ] [ Designated as safety issue: No ]
- All cause mortality during the hospitalization [ Time Frame: one year ] [ Designated as safety issue: No ]
- Bronchopulmonary dysplasia defined as oxygen requirements or ventilatory support needs at 36 weeks CGA [ Time Frame: one year ] [ Designated as safety issue: No ]
- Number of doses of surfactant [ Time Frame: one year ] [ Designated as safety issue: No ]
- Incidence of pneumothorax [ Time Frame: one year ] [ Designated as safety issue: No ]
- Total duration of oxygen requirement [ Time Frame: one year ] [ Designated as safety issue: No ]
- Incidence of nasal deformities, specifically nasal erosions [ Time Frame: one year ] [ Designated as safety issue: No ]
- Time to reach full volume feeds (at least 120 ml/kg/day) [ Time Frame: one year ] [ Designated as safety issue: No ]
- Time to regain birth weight [ Time Frame: one year ] [ Designated as safety issue: No ]
- Total length of hospital stay [ Time Frame: one year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: SiPAP |
Device: SiPAP - placebo
The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
|
| Experimental: Neurally Adjusted Ventilatory Assist |
Device: Neurally Adjusted Ventilatory Assist (NAVA)
Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
|
Eligibility| Ages Eligible for Study: | 28 Weeks to 32 Weeks |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Infants born greater than or equal to 28+0 weeks and less than or equal to 31+6 weeks gestation
- Diagnosis of RDS in the first 24 hours of life requiring respiratory support
- Parental consent obtained
Exclusion Criteria:
- Infants with a major congenital anomaly
- Infants with pulmonary hypoplasia
- Infants known or suspected to have a neuromuscular disorder
- Infants less than 28+0 weeks GA
- Intubated infants that are likely to require continued mechanical ventilation
- Infants requiring vigorous resuscitation at birth, including chest compressions +/- cardiac medications
Contacts and Locations| Contact: Rebecca Sherlock, MD | (604) 839-7345 | rsherlock73@gmail.com |
| Canada, British Columbia | |
| Surrey Memorial Hospital | Not yet recruiting |
| Surrey, British Columbia, Canada, V3V1Z2 | |
| Contact: Rebecca Sherlock, MD (604) 839-7345 rsherlock73@gmail.com | |
| Principal Investigator: Ravinder Kajla | |
| Sub-Investigator: Rebecca Sherlock, MD | |
| Principal Investigator: | Ravinder Kajla | Fraser Health |
| Study Chair: | Rebecca Sherlock, MD | Fraser Health |
More Information
No publications provided
| Responsible Party: | Ravinder Kajla, Respiratory Therapist, Clinical Resource Therapist, Fraser Health |
| ClinicalTrials.gov Identifier: | NCT01588080 History of Changes |
| Other Study ID Numbers: | NAVA |
| Study First Received: | April 26, 2012 |
| Last Updated: | April 29, 2012 |
| Health Authority: | Canada: Ethics Review Committee |
Additional relevant MeSH terms:
|
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Lung Diseases Respiratory Tract Diseases |
Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases |
ClinicalTrials.gov processed this record on May 23, 2013